UnknownNot Applicable

the Gut Microbiome and Metabolomics in Chronic Lower extreMities Threatening Ischemia

China120 participantsStarted 2021-11-15

Plain-language summary

Intestinal floras and their metabolites are involved in progressing metabolic and cardiovascular diseases. However, currently, articles related to the relationship between intestinal floras and atherosclerosis mainly focus on coronary atherosclerotic disease (CAD) population, or atherosclerosis model animals such as ApoE-/-, LDLR-/- high-fat diet mice, and there are few studies on Chronic limb-threatening ischemia (CLTI). CLTI and CAD have a similar pathological basis of atherosclerosis. It is unclear whether intestinal flora plays an essential role in the occurrence and development of CLTI. This project aims to explore the relation between microorganisms, metabolites, and CLTI.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Patients with inflammatory bowel disease, autoimmune diseases, malignancies, infectious diseases, and severe liver and kidney dysfunction (cirrhosis, CKD stage 4 and 5).
✕. Patients with thromboembolic angiitis, arterial embolism, and takayasu.
✕. Patients who have used probiotics or antibiotics in the last 2 months.
✕. After interventional surgery and amputation below the knee or above knee.

What they're measuring

Bacteria or metabolites associated with prolonged survival time without above-knee amputation

Timeframe: 3years.

Trial details

NCT IDNCT06220994

SponsorBeijing Tsinghua Chang Gung Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-05-15

View on ClinicalTrials.gov More Chronic Limb-threatening Ischemia trials